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Abstract
Background: In Mozambique, tuberculosis (TB) is thought to be the most common cause of death among antiretroviral
therapy (ART) enrollees. Monitoring proportions of enrollees screened for TB, and incidence and determinants of TB during
ART can help clinicians and program managers identify program improvement opportunities.
Methodology/Principal Findings: We conducted a retrospective cohort study among a nationally representative sample of
the 79,500 adults (.14 years old) initiating ART during 2004–2007 to estimate clinician compliance with TB screening
guidelines, factors associated with active TB at ART initiation, and incidence and predictors of documented TB during ART
follow-up. Of 94 sites enrolling .50 adults on ART, 30 were selected using probability-proportional-to-size sampling; 2,596
medical records at these sites were randomly selected for abstraction and analysis. At ART initiation, median age of patients
was 34, 62% were female, median baseline CD4+ T-cell count was 153/mL, and 11% were taking TB treatment. Proportions of
records with TB screening documentation before ART initiation improved from 31% to 66% during 2004–2007 (p,0.001). TB
screening compliance varied widely by ART clinic [n = 30, 2%–98% (p,0.001)] and supporting non-Governmental
Organization (NGO) [n = 7, 27%–83% (p,0.001)]. Receiving TB treatment at ART enrollment was associated with male sex
(p,0.001), weight ,45 kg (p,0.001) and CD4,50/mL (p = 0.001). Isoniazid preventive therapy (IPT) was prescribed to ,1%
of ART enrollees not taking TB treatment. TB incidence during ART was 2.32 cases per 100 person-years. Factors associated
with TB incidence included adherence to ART ,95% (AHR 2.06; 95% CI, 1.32–3.21).
Conclusion: Variations in TB screening by clinic and NGO may reflect differing investments in TB screening activities. Future
scale-up should target under-performing clinics. Scale-up of TB screening at ART initiation, IPT, and ART adherence
interventions could significantly reduce incident TB during ART.
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Introduction
In Mozambique, rising adult HIV prevalence from about 2% in
1990 to 11.5% in 2009 [1] has fueled the country’s tuberculosis
(TB) epidemic. During 1990–2010, TB case notification rates
increased from 401/100,000 population to 544/100,000 popula-
tion (a 36% increase), driven mainly by increases in TB-HIV co-
infection rates, from 51/100,000 population to 330/100,000
population (a 647% increase) [2]. With increases in TB-HIV
incidence, and high mortality among HIV-infected patients with
undiagnosed TB or diagnosed TB but no access to antiretroviral
therapy (ART), TB is thought to account for nearly a quarter of
Mozambique’s national HIV/AIDS mortality [3].
Although ART reduces TB acquisition risk among HIV-
infected persons by about 67% [4], high TB incidence is
commonly observed immediately after ART start [5]. Even after
years of therapy, TB incidence can be twice as high as that in the
general population [6]. Understanding expected TB morbidity
during ART is important for TB-HIV program managers for
planning purposes and for clinicians involved in patient manage-
ment [7].
Autopsy studies suggest that undiagnosed TB is a common
cause of mortality among HIV-infected patients [8–11]. There-
fore, monitoring the proportions of patients correctly screened for
TB prior to ART start is important for TB-HIV program
monitoring. Similarly, since late 2006, the Mozambican Ministry
of Health (MOH) began recommending isoniazid preventive
therapy (IPT) for HIV-infected persons when active TB has been
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excluded, and monitoring IPT uptake is an important TB-HIV
program monitoring activity.
Investigating risk factors associated with prevalent TB (active
TB at ART enrollment) and incident TB during ART follow-up is
important for clinicians to identify patients at risk, and can help
program managers identify program improvement opportunities.
Therefore, we conducted a retrospective cohort study among a
nationally representative sample of the 79,500 adult ART patients
who initiated therapy during 2004–2007 in Mozambique to
describe TB screening practices, the prevalence of active TB at
ART enrollment, IPT uptake among patients not taking TB
treatment at ART start, TB incidence during ART follow-up, and
factors associated with prevalent and incident TB.
Methods
Ethics Approval
This study was approved by the Institutional Review Board
(IRB) of the United States Centers for Disease Control and
Prevention (CDC) and the Mozambican MOH Ethics Review
Committee (Ministerio da Saude Comite Nacional de Bioetica para a
Saude). Both review boards approved the consent procedures.
Patient informed consent was not required as only routine,
anonymous, operational monitoring data were collected and
analyzed.
Eligibility for ART
During 2004–2007, patients diagnosed with World Health
Organization (WHO) stage IV HIV disease, stage III disease with
CD4+ T-cell (CD4) counts ,350/mL, or stage I or II disease with
CD4 counts,200/mL, were eligible for ART [12]. First-line ART
regimens included two nucleoside reverse-transcriptase inhibitors
(NRTI) and a non-nucleoside reverse transcriptase inhibitor
(NNRTI). Second-line regimens contained a protease inhibitor
and two new NRTIs.
TB Screening and Diagnosis
Mozambique guidelines recommend that HIV-infected adults
be screened for TB at all HIV clinic visits, including the ART
enrolment visit. However, during 2004–2006, national ART
guidelines did not specify recommended TB screening questions to
identify TB suspects. In 2007, a new TB screening instrument was
introduced which screened for: (1) cough for .3 weeks, (2) any
cough with blood, (3) night sweats .3 weeks, (4) fever .3 weeks,
(5) weight loss .3 weeks, and (6) any TB contacts [13]. From 2007
onwards, if one or more of these six TB symptoms were positive,
the patient was considered a TB suspect. For all TB suspects,
regardless of how they were identified during 2004–2008, two on-
the-spot sputum samples were sent to the laboratory for Ziehl-
Neelson sputum microscopy. For smear-negative TB suspects,
chest X-ray was recommended. TB culture, available at two
central Maputo laboratories [2], was seldom requested by
clinicians due to sample transport barriers, and long wait times
for results. If extra-pulmonary TB was suspected, lymph node
aspiration, lumbar puncture, and abdominal ultrasound were
additional diagnostic tests available at larger facilities. Usually TB
treatment was managed at TB clinics, separate from ART clinics.
Patient Monitoring
Mozambique guidelines recommend adults, who are newly
initiating ART, be seen frequently initially (at 2 weeks, monthly for
3 months, and quarterly thereafter) until stable on therapy and
then at least every 6 months, for weight measurements, clinical
staging, TB screening, hemoglobin measurements, and CD4 count
testing. At each visit, standard Ministry of Health (MOH)
recommended medical records are completed. During 2004–
2008, patients collected medications monthly from clinic pharma-
cies.
Study Design and Population
This was a secondary analysis of a retrospective cohort study
designed to assess incidence and predictors of attrition [death, loss
to follow-up (LTFU), or stopping ART], among a nationally
representative sample of adult ART patients (.15 at ART start),
who initiated ART during 2004–2007 in Mozambique [14]. This
analysis investigates factors associated with active TB at ART
initiation (prevalent TB) and incident TB during ART follow-up,
among those not taking TB treatment at ART initiation.
Treatment Outcome Measures
Any patient taking TB treatment (for pulmonary or extra-
pulmonary TB) at ART initiation was considered to have
prevalent TB at ART start. The first occurrence of TB treatment
(for pulmonary or extra-pulmonary TB) among adults, not on TB
treatment at ART initiation, was considered incident TB.
Exposure Variables
Variables routinely collected on the MOH-recommended ART
records, including age at ART start, sex, previous TB diagnoses,
weight, WHO stage, CD4 count, hemoglobin, and co-trimoxazole
prescription, were assessed as possible risk factors for prevalent and
incident TB. Laboratory machines and methods for measuring
CD4 counts and hemoglobin in Mozambique’s ART program,
have been previously described [14]. Similar to other cohort
studies in resource-constrained settings [15], adherence to ART
was estimated by measuring timeliness of patient visits to
scheduled medicine pick-up appointments at clinic-based phar-
macies during months 0–6 of ART [16–18].
Sample Size
To answer the original primary study question concerning
attrition with the desired precision, a sample size of .1,200
patient records was needed to achieve a 95% confidence interval
(CI) of +3.0% or smaller around a 25% [19] 6-month attrition
estimate, assuming a design effect of 1.5. A target sample size of
2,600 medical records was chosen to meet the needs of a
concurrent cost-effectiveness study.
Sampling
MOH-reported data from December 31, 2006, were used to
define the clinic sample frame. By December 2006, 43,295 adults
had initiated ART at 152 clinics. Clinics with ,50 adults enrollees
by December 31, 2006, were excluded from the sample frame to
improve study feasibility, resulting in 58 clinics, with 1,061 adult
ART enrollees, being excluded. Of the 94 clinics enrolling .50
adults on ART, 12 with .1,000 enrollees were selected with
certainty, while 18 with 50–1,000 enrollees were selected using
probability-proportional-to-size sampling; we aimed to randomly
sample 2,600 medical records of adults who initiated ART during
2004–2007 at these 30 sites. To meet the needs of a concurrent
cost-effectiveness study, 150 medical records were sampled at each
of 11 sites involved in this concurrent study (1,650 records); at the
remaining 19 sites, 50 medical records were randomly selected per
site (950 records). At each of the selected 30 sites, the desired
sample size of eligible medical records was randomly selected from
paper or electronic ART patient registers. If the paper medical
record of a selected patient was missing, the team searched in all
TB Incidence during ART – Mozambique
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Table 1. Associations between Patient Characteristics and Prevalence of Active TB at ART Initiation.








(n =2,325, imputed) P-value**
Original* Imputed
N N %/median IQR/CI %/median IQR/CI Median/% IQR/CI Median/% IQR/CI
Age at enrolment
Median (IQR) year 2,596 2,596 34 (28–42) 34 (28–42) 36 (29–42) 34 (28–42) 0.513
Sex
Female 1,576 2,596 62% (59–65) 62% (59–65) 52% (48–56) 63% (60–66) 0.003
Male 1,020 2,596 38% (35–41) 38% (35–41) 48% (44–52) 37% (34–40)
Marital Status
Civil union|married 1,152 2,363 47% (44–51) 47% (43–51) 53% (47–59) 53% (49–57) 0.226
Single|widowed 1,211 2,363 53% (49–56) 53% (49–57) 47% (41–53) 47% (43–51)
Missing 233 2,596 9%
Employment
Employed 992 2,268 46% (40–51) 45% (40–51) 47% (42–51) 45% (39–51) 0.764
Student 107 2,268 4% (3–5) 4% (3–5) 6% (3–8) 4% (3–5)
Unemployed 1,169 2,268 50% (45–56) 51% (45–56) 47% (43–51) 51% (45–57)
Missing 328 2,596 13%
WHO Stage
Stage I/II 619 1,617 37% (32–42) 41% (35–47) 6% (3–9) 45% (39–52) ,0.001
Stage III 739 1,617 47% (43–52) 44% (38–49) 61% (53–70) 42% (36–47)
Stage IV 259 1,617 16% (13–18) 15% (12–18) 33% (24–42) 13% (10–16)
Missing 979 2,596 38%
Weight
.60 kg 470 2,061 17% (14–20) 18% (15–21) 13% (9–17) 27% (23–30) ,0.001
45–60 kg 1,224 2,061 59% (56–61) 57% (53–60) 52% (45–59) 57% (54–60)
,45 kg 367 2,061 24% (21–27) 25% (22–29) 34% (29–40) 16% (13–19)
Missing 535 2,596 21%
CD4 Count
$200/mL 754 2,254 34% (28–39) 33% (28–38) 20% (15–25) 35% (29–41) 0.001
50 – ,200/mL 1,144 2,254 50% (46–54) 50% (46–54) 54% (49–59) 50% (46–54)
,50/mL 356 2,254 16% (14–18) 17% (14–19) 26% (23–29) 15% (13–17)
Missing 342 2,596 13%
Hemoglobin
$8 g/dL 1,664 1,899 87% (85–88) 86% (84–88) 75% (69–81) 87% (85–90) ,0.001
,8 g/dL 235 1,899 13% (12–15) 14% (12–16) 25% (19–31) 13% (10–15)
Missing 697 2,596 27%
Co-trimoxazole
Prescribed CTX 821 2,596 31% (26–36) 31% (26–36) 33% (26–40) 31% (26–35) 0.819
Not prescribed CTX 1775 2,596 69% (64–74) 69% (64–74) 67% (60–74) 69% (65–74)
Adherence
$95% adherent 1,263 1,860 73% (67–79) 72% (66–78) 76% (69–84) 72% (66–78) 0.958
,95% adherent 597 1,860 27% (21–33) 28% (22–34) 24% (66–78) 28% (22–34)
Missing 736 2,596 28%
Site Size
.1,000 487 2,596 23% (10–37) 23% (10–37) 22% (7–37) 24% (10–38) 0.831
#1,000 2,109 2,596 77% (63–90) 77% (63–90) 78% (63–93) 76% (62–90)
Previous TB
No 2,077 2,596 80% (77–82) 80% (77–82) 11% (8–13) 88% (87–90 ) ,0.001
Yes 519 2,596 20% (18–23) 20% (18–23) 89% (87–92) 12% (10–13)
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likely locations at the clinic (e.g. pharmacy, consulting room, or
social worker’s office). If not found, a replacement medical record
was randomly selected. Data from selected records were abstracted
in November 2008.
Analytic Methods
Data were analyzed using SAS 9.2 (SAS Institute Inc., Cary,
NC), and STATA 10 (StataCorp, 2009, Stata Statistical Software,
Release 10, College Station, TX). Data were weighted and survey
design controlled for, during analysis.
Multiple imputation with chained equations was used to impute
missing baseline demographic and clinical data for covariates of
interest [20]. The ice [21–23] procedure in Stata was used to
create 20 imputed datasets. The imputation model included
incident TB as the event indicator, all study variables, and the
Nelson-Aalen estimate of cumulative hazard [24]. Missing data
were assumed missing at random (MAR) and all patients had
complete time-to-event data (i.e., all patients had an ART
initiation date, outcome status by November 2008, and date of
outcome).
Associations between baseline covariates and active TB at ART
start (prevalent TB) were assessed using bivariate logistic
regression, with random effects specified for each facility. The
sensitivity of the quadrature approximation was checked for
random effects logistic regression models. Estimates across
imputed datasets were combined according to Rubin’s rules [20]
using the mim procedure in Stata [25].
Because medical records did not indicate timing of TB
treatment cessation for those patients taking TB treatment at
ART enrollment, time-to-event analysis to assess incidence and
determinants of TB during ART follow-up was restricted to those
patients considered TB-free at ART enrollment. The event of
interest was first incidence of pulmonary or extra-pulmonary TB.
Patients not documented to have been diagnosed with TB during
ART follow-up were censored at the most recent visit, date of
death if death occurred, or date of transfer if transferred. Cox
proportional hazards regression models were used to estimate
adjusted hazard ratios and 95% confidence intervals (CI). The
proportional hazards assumption was assessed using visual
methods and the Grambsch and Therneau test [26]. Estimates
were combined across the imputed datasets according to Rubin’s
rules [20] using the mim procedure in Stata [25].
Kaplan-Meier curves were used to examine cumulative
probability of remaining undiagnosed with TB over time stratified
by baseline variables.
Results
Data for 2,596 adult patients enrolled on ART during 2004–
2007 were abstracted and analyzed. At ART initiation, median
age was 34, 62% were female, and median CD4 count was 153/
mL (IQR, 76–231/mL), being lower for males than females (139/
mL vs. 159/mL, p,0.01). Prior completed TB treatment was
documented for 20% of patients, while 11% of patients (95% CI,
9–13%), had active TB at ART start (prevalent TB) (table 1).
Compared with patients not diagnosed as having prevalent TB
at ART enrollment, patients with prevalent TB were more likely to
be males (48% vs. 37%, p,0.001), have WHO stage III or IV
disease (94% vs. 55%, p,0.001) (table 1), have weight ,45 kg
(34% vs. 16%, p,0.001), have a CD4 count ,50/mL (26% vs.
15%, p= 0.001), have hemoglobin ,8 g/dL (25% vs. 13%,
p,0.001), and have been treated for TB prior to the current TB
diagnosis (89% vs. 12%, p,0.001).
Efavirenz combined with lamivudine (3TC), and stavudine
(d4T) or zidovudine (AZT), was prescribed to 73% of patients with
active TB versus only 2% of patients assessed as TB-free (p,0.001)
(table 1). In contrast, Nevirapine with 3TC, and d4T/AZT was
prescribed to 97% of patients assessed as TB-free versus 22% of
active TB patients at baseline (p,0.001).
Among all ART enrollees, 61% (53–69%) had some documen-
tation of TB screening in their medical records (figure 1A). The
most common symptoms screened for were chronic cough (55%)
and chronic fever (52%). Only 5% of ART enrollees during 2004–
2007 were screened for all six recommended TB symptoms.
Proportions of ART patients receiving some form of TB screening
increased from 31% in 2004 to 66% in 2007 (p,0.001) (figure 1B).
Proportions of ART enrollees with some documentation of TB
screening in the records varied significantly by site, from 2% to
98% (p,0.001) (figure 2A). Larger sites [.1,000 patients (n = 12)]
did not differ from smaller sites [,1,000 (n= 18)] in TB screening
compliance (60% vs. 64%, p= 0.647) and rural sites (n = 9) did not
differ from urban sites (n = 21) in TB screening compliance (67%
vs. 58%, p= 0.188). However, all 30 clinics were supported by one
of seven non-Governmental organizations (NGOs), and TB
Table 1. Cont.








(n =2,325, imputed) P-value**
Original* Imputed
N N %/median IQR/CI %/median IQR/CI Median/% IQR/CI Median/% IQR/CI
Regimen
d4T/AZT+3TC+NVP 2311 2,596 89% (86–92) 86% (86–92) 22% (16–29) 97% (95–99) ,0.001
d4T/AZT+3TC+EFV 244 2,596 10% (8–12) 8% (8–12) 73% (66–80) 2% (1–3)
AZT/d4T+3TC+ABC 17 2,596 1% (0–1) 0% (0–1) 4% (1–8) 0% (0–1)
Other 24 2,596 1% (0–2) 0% (0–2) 0% (0–1) 1% (0–2)
Abbreviations: TB, tuberculosis; ART, antiretroviral therapy; IQR, inter-quartile range; CI, 95% confidence interval; WHO, World Health Organization; CTX, Co-trimoxazole;
d4T, stavudine; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; ABC, abacavir.
*Data in this column has been previously published [14].
**Compares characteristics of patients receiving (n = 271) and not receiving (n = 2,325) TB treatment at ART initiation.
doi:10.1371/journal.pone.0054665.t001
TB Incidence during ART – Mozambique
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54665
screening compliance was associated with the NGO providing
support (figure 2B).
Only three patients not taking TB treatment at ART start
[0.1% (95% CI, 0.0–0.2%)] were prescribed isoniazid preventive
therapy (IPT).
Among the 2,325 patients, who were considered TB-free at
ART start by attending clinicians, 72 were diagnosed with
pulmonary TB and 14 with extra-pulmonary TB during 3,438
person-years of ART follow-up, with an overall TB incidence rate
of 2.32 cases per 100 person-years (95% CI, 1.80–3.05). TB
Figure 1. Compliance with TB Screening among ART Enrollees. A TB Screening among Patients at ART Enrollment in Mozambique during
2004–2007 (n = 2,596). * ‘‘Other’’ includes patients taking TB treatment at ART initiation, or for whom ‘‘No TB’’ or ‘‘TB screen negative’’ was written in
the medical record. B Improvement in Proportions of ART Enrollees Screened for TB in Mozambique during 2004–2007 (n = 2,596).
doi:10.1371/journal.pone.0054665.g001
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incidence rates did not vary significantly across 3-monhtly ART
follow-up intervals (figure 3).
Baseline characteristics associated with increased risk of TB
incidence included a 10-year age increase [adjusted hazards ratio
(AHR) 1.40; 95% CI, 1.23–1.60] (table 2). Compared with
Figure 2. Compliance with TB Screening at ART Enrollment by Clinic and Supporting Non-Governmental Organization. A Compliance
with TB Screening Guidelines According to ART Clinic (n = 2,596). Chi-square test: p,0.001. B Compliance with TB Screening Guidelines According to
Primary Non-Governmental Agency Supporting the ART Clinic (n = 2,596). Chi-square test: p,0.001.
doi:10.1371/journal.pone.0054665.g002
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employed patients, students had lower TB incidence (AHR 0.20;
95% CI, 0.07–0.55). Compared with patients having a weight
.60kg at ART start, patients with a weight of 45–60 kg (AHR
2.52, 95% CI 0.91–7.01, p = 0.066) or ,45 kg (AHR 3.50, 95%
CI 0.84–14.54, p = 0.075) tended to have higher incidence of TB
diagnosis (figure 4A). Similarly, compared with patients having a
CD4.200/mL, patients with a CD4,50/mL tended to have
higher TB incidence rates (AHR 1.79, 95% CI, 0.94–3.44,
p = 0.074). Compared with patients assessed as having ART
adherence .95%, patients with adherence ,95% had higher TB
incidence rates (AHR 2.06, 95% CI, 1.32–3.21) (figure 4B).
Compared with patients for whom no documentation of TB
screening at ART initiation was found, patients with documented
TB screening at ART start had higher incidence of TB diagnosis
during follow-up (AHR 1.60, 95% CI, 1.12–2.28) (figure 4C).
Discussion
This is the first nationally representative survey of TB screening,
IPT uptake, and TB morbidity among enrollees in Mozambique’s
national ART program and has several important findings. Firstly,
the prevalence of TB at ART initiation and incidence of TB
during ART follow-up were significantly higher than current
estimates of TB prevalence and incidence in Mozambique’s
general population [2]. Secondly, only 61% of ART enrollees had
some documentation of TB screening, with TB screening
compliance varying significantly by ART clinic and supporting
NGO, suggesting that TB screening scale-up initiatives targeted at
under-performing clinics and NGO partners, may be an efficient
way to improve compliance with screening guidelines. Thirdly,
IPT uptake was low with,1% of patients not taking TB treatment
at ART initiation, receiving isoniazid. Fourthly, TB prevalence
and incidence were associated with markers of advanced disease at
ART initiation, suggesting that initiation of ART at earlier disease
stages, could be an important TB prevention strategy [27]. Finally,
patients with lower adherence to ART during the first 6 months of
ART were more likely to develop incident TB during follow-up,
suggesting that ART adherence interventions could help to reduce
TB morbidity among ART patients.
TB Burden
Our reported prevalence of active TB at ART start (11%) is 22
fold higher than that estimated for the general population (0.5%)
[2]. The 11% prevalence is the same as that reported from Zambia
[15], where national background TB incidence (566/100,000 in
2005 [2]), and median baseline CD4 count (143/mL) were similar.
However, higher prevalence of TB among ART enrollees (21%)
has been reported from South African settings where background
TB incidence was higher (925/100,000 in 2005 [2]) and mean
CD4 count at ART initiation lower (about 119/mL) [7]. Higher
prevalence has also been reported among South African ART
enrollees when TB culture was employed as a universal TB
screening method; true TB prevalence rates of 15.5% [28], 17.3%
[29], 25.7% [30], and 31.5% [31] have been reported in these
settings. Our overall reported TB incidence rate of 2.32/100
person-years (95% CI, 1.80–3.05) is similar to that reported from
routine program settings in Uganda (3.14/100 PY, 95% CI 2.82–
3.49) [32], and Coˆte d’Ivoire (4.8/100 PY, 95% CI 2.5–8.3) [33],
but slightly lower than that reported from South Africa (4.2/100
PY, 95% CI 3.8–4.5) [7]. Our reported TB incidence rate is about
four-fold higher than that estimated for the general population in
Mozambique in 2005 (554/100,000 population) [2].
Unlike other studies, TB incidence in our cohort did not decline
with duration on ART [34]. Lack of decline in TB incidence rates
during ART has been observed in ART cohorts where universal
TB screening with TB culture prior to ART initiation has been
implemented [31]. It is unlikely that intensive TB screening
explains the lack of variation in TB incidence in our cohort, since
only 5% of patients received the full six-symptom TB screen. One
possible explanation is that undiagnosed symptomatic and sub-
clinical TB present at ART initiation, which should have
contributed to high early TB incidence rates during ART, went
undiagnosed at the ART clinic, and may have contributed to high
early rates of loss to follow-up (e.g. through hospitalization) or
mortality [14].
TB Screening and IPT Prescription
Formal TB screening criteria were not included in the national
ART guideline document until 2007. In the same year, national
Figure 3. TB Incidence Rates during ART Follow-up among Patients Assessed as TB-free at ART Initiation (n=2,325).
doi:10.1371/journal.pone.0054665.g003
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efforts to increase TB screening compliance were implemented,
especially by certain NGOs [13]. This probably explains the low
prevalence of TB screening in 2004–2006, improvement in TB
screening practices over time, and the association between TB
screening and the NGO allocated to provide primary support for
ART scale-up [13]. IPT for all HIV-infected patients in whom
active TB has been excluded was only recommended by MOH in
late 2006. This and the sub-optimal rates of TB screening at ART
Table 2. Cox Proportional Hazards Analysis of Patient Characteristics Associated with TB Incidence during ART Follow-up.
Original Crude Adjusted
No Rate/100 HR (95% CI) p AHR (95% CI) p
Age* 2,325 – 1.41 (1.25–1.58) ,0.001 1.40 (1.23–1.60) ,0.001
Sex
Female 1,576 1.90 1.00 1.00
Male 749 3.06 1.59 (1.21–2.09) 0.003 1.47 (0.95–2.27) 0.081
Marital Status
Civil union|married 1,152 2.46 1.00 1.00
Single|widowed 1,211 2.18 0.86 (0.60–1.22) 0.365 1.08 (0.71–1.63) 0.114
Employment
Employed 992 2.80 1.00 1.00
Student 107 0.36 0.12 (0.05–0.30) 0.003 0.20 (0.07–0.55) 0.010
Unemployed 1,169 2.04 0.76 (0.56–1.03) 0.072 0.90 (0.63–1.29) 0.536
WHO Stage
Stage I/II 619 2.06 1.00 1.00
Stage III 739 2.15 1.17 (0.64–2.12) 0.550 0.87 (0.41–1.85) 0.559
Stage IV 259 4.23 2.15 (0.88–5.20) 0.080 1.83 (0.55–6.05) 0.663
Weight
.60 kg 470 1.17 1.00 1.00
45–60 kg 1,224 2.63 2.35 (0.88–6.29) 0.073 2.52 (0.91–7.01) 0.066
,45 kg 367 3.64 3.16 (0.93–10.77) 0.061 3.50 (0.84–14.54) 0.075
CD4 Count
$200/mL 754 1.37 1.00 1.00
50–,200/mL 1,144 2.60 1.68 (1.00–2.84) 0.052 1.45 (0.84–2.49) 0.165
,50/mL 356 3.55 2.26 (1.21–4.23) 0.015 1.79 (0.94–3.44) 0.074
Hemoglobin
.8 g/dL 1,664 2.16 1.00 1.00
,8 g/dL 235 3.60 1.79 (0.96–3.35) 0.065 1.40 (0.63–3.11) 0.365
Co-trimoxazole
Prescribed CTX 821 2.55 1.00 1.00
Not prescribed CTX 1775 2.21 0.82 (0.61–1.11) 0.180 0.98 (0.71–1.36) 0.919
Adherence
$95% adherent 1,263 1.92 1.00 1.00
,95% adherent 597 3.54 1.88 (1.29–2.73) 0.003 2.06 (1.32–3.21) 0.004
Site Size
.1,000 487 2.34 1.00 1.00
#1,000 2,109 2.24 0.93 (0.62–1.40) 0.700 0.75 (0.48–1.15) 0.170
Previous TB
No 2,077 2.28 1.00 1.00
Yes 519 2.59 1.15 (0.67–1.98) 0.591 0.89 (0.48–1.67) 0.708
Screened at Baseline
Not screened 1,190 2.28 1.00 1.00
Screened 1,406 2.59 1.81 (1.23–2.67) 0.005 1.60 (1.12–2.28) 0.013
Abbreviations: HR, hazards ratio; AHR, adjusted hazards ratio; TB, tuberculosis; CI, confidence interval; WHO, World Health Organization; CTX, Co-trimoxazole.
*Hazard ratio is reported for every 10 year increase in age at ART start.
doi:10.1371/journal.pone.0054665.t002
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initiation likely explain the low rates of IPT prescription during
2004–2007. Another barrier to IPT scale-up may have been
clinician concerns about isoniazid resistance. Even though
available evidence suggests that the effect of IPT scale-up on
isoniazid resistance is likely to be small [35], limited ability to
definitively exclude active TB with available TB diagnostic tests
(e.g. smear microscopy) and limited ability to monitor and ensure
IPT adherence in a resource-constrained environment [36], may
have hindered widespread IPT use [4]. Because both TB screening
and IPT prescription for eligible patients at ART enrollment are
important morbidity reduction and infection control interventions
[37], uptake of these services should be monitored to assess
continued improvement over time.
In our study, TB symptom screening at ART start was also
associated with TB diagnosis and treatment during ART follow-
up, with most differences in TB incidence noted after two years of
Figure 4. Kaplan Maier Analysis of TB-Free Survival. A Kaplan Meier Curve of TB Incidence Stratified by Baseline Weight. B Kaplan Meier Curve
of TB Incidence Stratified by Level of ART Adherence. C Kaplan Meier Curve of TB Incidence Stratified by TB Screening at ART Start.
doi:10.1371/journal.pone.0054665.g004
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follow-up (figure 4C). This could reflect the likelihood that
clinicians who comply with TB screening guidelines at ART
initiation will also screen for TB during long term ART follow-up
[38], or it could reflect higher rates of LTFU or death among
patients not screened for TB at ART start.
Importance of Early ART
As in other studies, prevalence of TB at ART start was
associated with markers of advanced disease (advanced WHO
stage, previous TB, weight ,45 kg, low CD4 count, and
hemoglobin ,8 g/dL) [7]. Similarly, markers of under-nutrition
(weight,45 kg) and immune suppression (CD4,50/mL) tended to
be associated with TB incidence during ART follow-up
[5,7,32,39]. Slower immune recovery during ART among older
HIV-infected individuals [40,41] may explain the higher rates of
TB incidence in older ART patients. The association between TB
and markers of advanced disease suggests that earlier treatment
with ART, limiting time spent at low CD4 counts, could be an
important TB prevention strategy for HIV-infected persons
enrolled in care [27].
Importance of ART Adherence
Poor adherence to antiretroviral pick-up appointments during
months 0–6 of ART was associated with increased TB incidence.
The poor adherence to pharmacy drug pick-up appointments
could reflect higher risk for virological failure and slower immune
recovery [17,18], which has been associated with incident TB
among ART cohorts in Europe and North America [38]. An
alternative explanation for higher observed TB incidence among
non-adherent patients, is that concurrent TB treatment caused
poor adherence to antiretroviral drug pick-up appointments,
however our own study showed no association between TB
treatment at ART start and subsequent poor ART adherence, and
other studies have reported no association between concurrent TB
treatment and lower ART adherence [42]. As has been proposed
by other authors, improving ART adherence could be an
important intervention to reduce TB burden during ART [38].
Limitations
This analysis has several limitations, including: (1) missing data
on baseline covariates probably introduced non-differential
measurement error, (2) we excluded patients with active TB at
ART initiation from the time-to-event analysis; therefore, reported
TB incidence rates may not be representative of these patients, (3)
TB diagnostic results for some TB suspects identified at ART
initiation may have returned after ART start, such that some
reported incident TB may represent delayed diagnosis of prevalent
TB at ART initiation, (4) follow-up time during later years of ART
(e.g., years 2–4) may not be representative of patients enrolled
during the latter parts of 2004–2007 because data were abstracted
in November 2008, (5) because TB treatment clinics were usually
run separately from ART clinics, some incident TB cases may not
have been recorded in the ART medical records, and (6) similar to
other studies [7,32,33] our study reports incidence of diagnosed
and treated TB which may be an under-estimate of true TB
incidence due to missed TB diagnoses (e.g. failure to identify TB
suspects due to inconsistent TB screening during ART), or an
over-estimate of true TB incidence due to incorrect initiation of
TB treatment for some smear-negative TB suspects.
Conclusions
The clinical burden of TB among ART enrollees was
significant, increasing the importance of TB screening scale-up
initiatives, IPT scale-up for adults screening negative, earlier ART
to limit time spent at low CD4 counts, and adherence
interventions for new ART enrollees.
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